News | EP Lab | February 02, 2021

Patient Data From Several Cardiac Devices Streamlined Into One Platform With New Cloud-based Software

Optimize EP launches CaRM cardiac device data management platform to automates workflow processes and enhances data algorithms

The Optimize EP CaRM software integrates data from several EP devices a patients may use and aggregate it into one location.

The Optimize EP CaRM software integrates data from several EP devices a patients may use and aggregate it into one location. 


February 2, 2021 – Optimize EP, a digital health company focused on transforming cardiac care by improving the current state of cardiac data management, recently emerged from stealth mode to announce the launch of CaRM, the company’s unique cloud-based software that streamlines patient data from multiple electrophysiology (EP) cardiac devices onto one accessible and easy-to-use platform. 

Founded by Maninder Bedi, M.D., who also serves as the company’s chief medical officer, Optimize EP incorporates both enterprise performance management (EPM) and electronic medical record (EMR) systems effortlessly into the CaRM software. It features data algorithms designed specifically to help physicians, clinical teams and administrators overcome the challenges associated with codifying and simplifying the immense amount of remote monitoring data transmitted each day so care teams can deliver improved and differentiated patient care. 

“Remote monitoring has the potential to dramatically improve patient care, but the reality of managing cardiac device data is daunting; it can be chaotic and time-consuming,” Bedi said, who is a practicing electrophysiologist with Regional Cardiac Arrhythmia in Steubenville, Ohio. “CaRM can streamline data from both implantable and external devices and features a number of automated processes that simplify day-to-day workflow, making it possible for clinical teams to devote more time to treating more patients.” 

CaRM integrates a variety of hospital and clinic billing software programs, ensuring the accuracy of reimbursement codes and the essential capture of associated revenue. The platform can be customized to create unique alerts and notifications, increasing the functionality and simplicity of the interface. CaRM also syncs directly with the FDA’s product recall page, automatically and immediately alerting physicians to any FDA recall announcements impacting their patients’ devices, giving them the opportunity to adjust treatment strategies and alter care quickly. 

“On the clinical side of things, CaRM can make patient care easier, but for hospitals and clinics, it can also strengthen their operational margins,” said Ravi Kartan, president and CEO of Optimize EP. “CaRM is an invaluable tool for those EPs and cardiologists who own their practices and rely on intuitive technologies like ours to keep things up and running. It’s a practical digital tool for sustainability and profitability.” 

CaRM is commercially available in the United States.

Founded in 2018, Optimize EP is a digital health company focused on transforming cardiology care by improving cardiac data management to create sustainable, profitable practices that deliver optimal patient care. CaRM, the company’s proprietary software developed by a practicing electrophysiologist, is a cloud-based platform that improves efficiency and streamlines the clinical and administrative operations necessary for efficient cardiac device remote monitoring, reimbursement and billing.

For more information: https://www.optimizeep.com


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now